Institutional members access full text with Ovid®

Share this article on:

Health Physics Consequences of Out-Patient Treatment of Non-Hodgkin's Lymphoma with 131I-radiolabeled Anti-B1 Antibody.

Ryan, Michael T.; Spicer, K. M.; Frei-Lahr, Debra; Sarnei, Ehsan; Frey, G. Donald; Hargrove, Henry; Bloodworth, Glen
Health Physics: November 2000
Operational Topic: PDF Only

The Medical Utiiversity of South Carolina is cirrreiitly participating in clinical trials of 131I radiolabeled Anti-B1 antibody for treatment of Non-Hodgkin's lymphoma. Under current Soutli Carolina Department of Health and Environmental Control regulatory guidelines, ++ these patients are required to be admitted to the hospital and to remain as inpatients until the whole body burden is < 30 mCi or the exposure rate measured 1 m form the patient is <5 mR h-1. We demonstrate that these patient can be released in accordance with the new recommended guidelines of the Nuclear Regulatory Commission[S] for the release of patients containing radioactive materials in compliance with all radioactive material and publicdose standards. This benefits these patients by reducing their risk of infection and other hospital insults and by reducing the length of hospitalizations. Further, unnecessary hospital admissions are decreased, and the overall cost of healthcare delivery for these patients is significantly reduced.

(C)2000Health Physics Society